-
Mashup Score: 0BD teams up with MD Anderson, Su Clinica to study HPV self-collection tests in underserved Texas communities - 3 day(s) ago
After collecting an FDA greenlight earlier this year, BD is launching a real-world study to see if its self-collection kits for HPV testing will improve cervical cancer screening rates am | BD’s HPV test received an FDA approval in May, alongside a test developed by Roche, that allows women to skip the traditional Pap smear exam.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1After ALS trial misses mark, Seelos has filed for bankruptcy - 3 day(s) ago
After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for bankruptcy. | After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for chapter 11 bankruptcy.
Source: www.fiercebiotech.comCategories: General Medicine News, Rare DiseaseTweet-
After ALS trial misses mark, Seelos has filed for bankruptcy https://t.co/CNno2yq0NG
-
-
Mashup Score: 0
The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients for atrial fibrillation without relying on the electrical sign | The FDA’s de novo clearance brings afib screening to a wearable device with a most familiar form factor.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet-
#FDA clears @OmronHealthUS #bloodpressure cuff with #afib pulse wave detection https://t.co/ymkqgl8lbu
-
-
Mashup Score: 0
Caris Life Sciences has obtained an FDA approval for its MI Cancer Seek tumor profiling assay, unlocking its use as a companion diagnostic for multiple targeted medications across several | The company describes the precision medicine test as the first of its kind to offer simultaneous whole exome sequencing and whole transcriptome sequencing.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet-
.@Carisls scores #FDA approval for multi- #cancer #companiondiagnostics test | #diagnostics https://t.co/l4VdjNQIKV
-
-
Mashup Score: 0
23andMe is shutting down its therapeutics development division and plans to seek out buyers to find a new home for its in-house pipeline of DNA-informed immuno-oncology antibody drugs.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet-
.@23andMe shutters #cancer drug #research programs, lays off 40% of staff | #genetictesting https://t.co/b2nFSqxxWX
-
-
Mashup Score: 2
Trace Medicine has launched with $101 million in series A funds and a mission to treat amyotrophic lateral sclerosis (ALS) by targeting the same protein that recently caught the attention of Eli Li | Trace Medicine has launched with $101 million in series A funds and a mission to treat amyotrophic lateral sclerosis (ALS) by targeting the same protein that recently caught the attention of Eli Lilly.
Source: www.fiercebiotech.comCategories: General Medicine News, Rare DiseaseTweet-
Third Rock-backed Trace uses $101M series A to go after same ALS target as Lilly https://t.co/zBwcr0dk9w
-
-
Mashup Score: 23
Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma giant canned its clinical-stage gene therapy for the disease. | Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma giant canned its phase 1 gene therapy for the disease.
Source: www.fiercebiotech.comCategories: General Medicine News, Hem/OncsTweet-
The end of the road for SerpinPC. Development of this activated protein C inhibitor has been halted. Reasons are commercial and follow the approval of the new anti-TFPI and gene therapy agents for hemophilia B. https://t.co/Z7Dn6LGJij #hemophilia #SerpinPC
-
-
Mashup Score: 0
During quarterly earnings calls across the medtech industry, a recurring question has been on investors’ minds: If President-elect Donald Trump implements his plans for blanket 10% to 20% | During quarterly earnings calls this week across the medtech industry, a recurring question has been on investors’ minds.
Source: www.fiercebiotech.comCategories: General Medicine News, Future of MedicineTweet-
What #medtech CEOs are saying this week about #Trump's potential tariffs | #medicaldevices https://t.co/rAnKkxpnh9
-
-
Mashup Score: 1
AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last year led the company to shed almost all of its staff. Now, the immunotherapy biotech has found a new path forward by acquiring eye disease biotech Kalaris Therapeutics.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet-
Happy to see this -> https://t.co/IW6poziYwv @FierceBiotech
-
-
Mashup Score: 0
Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of Alzheimer’s disease. | The two plasma-based, in vitro tests scan for specific proteins linked to changes in the brain to help rule out the chances of Alzheimer’s among people showing cognitive decline.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet-
.@Roche collects more data to support blood tests for diagnosing #Alzheimers disease | #diagnostics #neurodegenerative diz. https://t.co/bivnStdX8S
-
.@BDandCo teams up with @MDAndersonNews @Su_Clinica to study #HPV self-collection tests in underserved #Texas communities | #vaccines #screening https://t.co/J1z8clwi1s